Litcius/Paper detail

An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses

Lihong Liu, Sho Iketani, Yicheng Guo, Eswar R. Reddem, Ryan G. Casner, Manoj S. Nair, Jian Yu, Jasper Fuk‐Woo Chan, Maple Wang, Gabriele Cerutti, Zhiteng Li, Nicholas C. Morano, Candace Castagna, Laura Corredor, Hin Chu, Shuofeng Yuan, Vincent Kwok‐Man Poon, Chris Chung‐Sing Chan, Zhiwei Chen, Yang Luo, Marcus H. Cunningham, Alejandro Chavez, Michael T. Yin, David S. Perlin, Moriya Tsuji, Kwok-Yung Yuen, Peter D. Kwong, Zizhang Sheng, Yaoxing Huang, Lawrence Shapiro, David D. Ho

2022Science Translational Medicine66 citationsDOIOpen Access PDF

Abstract

The devastation caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made clear the importance of pandemic preparedness. To address future zoonotic outbreaks due to related viruses in the sarbecovirus subgenus, we identified a human monoclonal antibody, 10-40, that neutralized or bound all sarbecoviruses tested in vitro and protected against SARS-CoV-2 and SARS-CoV in vivo. Comparative studies with other receptor-binding domain (RBD)-directed antibodies showed 10-40 to have the greatest breadth against sarbecoviruses, suggesting that 10-40 is a promising agent for pandemic preparedness. Moreover, structural analyses on 10-40 and similar antibodies not only defined an epitope cluster in the inner face of the RBD that is well conserved among sarbecoviruses but also uncovered a distinct antibody class with a common CDRH3 motif. Our analyses also suggested that elicitation of this class of antibodies may not be overly difficult, an observation that bodes well for the development of a pan-sarbecovirus vaccine.

Topics & Concepts

AntibodyMotif (music)Computational biologyMedicineBiologyImmunologyVirologyPhysicsAcousticsAnimal Virus Infections StudiesVirus-based gene therapy researchViral Infections and Immunology Research